A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer

Exclusion Criteria

• •known hypersensitivity to MonoFer® or FERINJECT®,
• •severe, known hypersensitivity to other intravenous iron preparations,
• •Plasma Phosphate \< 2.5 mg/dl at screening,
• •Hemochromatosis,
• •Untreated hyperparathyroidism,
• •Renal replacement therapy/kidney transplantation,
• •Active malignant disease, disease-free survival for less than 5 years,
• •Intravenous iron administration within the last 30 days,
• •Treatment with erythropoietin or erythropoietin-stimulating agents, transfusion of red blood cells, radiotherapy or chemotherapy within the last 60 days,
• •Surgery under anesthetic within the last 10 days,
• •Alanine transaminase (ALT) or aspartate transaminase (AST) \> 1.5 fold above levels in healthy individuals,
• •Acute febrile infections within the last 7 days,
• •Chronic inflammatory diseases requiring a systemic antiinflammatory treatment,
• •self-reported severe asthma or eczema,
• •presence of relative contraindications (any allergy, any immunologic or inflammatory disease, history of atopic allergies), for which a treatment with the medicinal investigational products is not deemed indicated by the investigator,
• •pregnancy,
• •women of childbearing potential without an effective method of contraception,
• •lactating women,
• •Present alcohol or drug dependency,
• •Patients with a history of a psychological illness or seizures,
• •Non-compliance or administration of any investigational drug within 30 days preceding the study start.